{"author_id": "1136370591517290496", "text": "RT @11Graphs: \u2605\u2606 #Stocks Near 52-Weeks Low \u2606\u2605\n\n(1/9)\nMost profitable by EBITDA Margin:\n1. \ud83c\udde8\ud83c\udde6 CANADIAN NATIONAL RAILWAY $CNI: 50.5%\n2. \ud83c\uddfa\ud83c\uddf8 PF\u2026", "id": "1243946659786211330", "created_at": "2020-03-28T17:02:49.000Z"}
{"author_id": "908994764963504129", "text": "$PFE (21%) YTD Loss to $31\n\n'19 YOY:\nRev: $51.8B, down (3.5%)\nGain: $16.3B\n\n8% Growth from Biopharma: Ibrance, Eliquis, Xeljanz &amp; Vyndaqel\n\nRepurchases: $5.3B\n\nCOVID-19 will delay $PFE Upjohn merger w/ $MYL by end of '20, will become Viatris\n\nMA (50): $35.3\n\n'20 Outlook\nRev: $51B https://t.co/i8rDMx0723", "id": "1243946536691806208", "created_at": "2020-03-28T17:02:20.000Z"}
{"author_id": "1020482099034427392", "text": "$AVEO is expected to file an NDA for the treatment of relapsed/refractory RCC by the end of March. AVEO hopes to compete with fellow VEGF agents marketed by $PFE $RHHBY $SNY $EXEL $NVS\n\n#stocks #money  \n\nSee all approved VEGF agents and indications at https://t.co/08M0lboVnh", "id": "1244030379448770561", "created_at": "2020-03-28T22:35:30.000Z"}
